VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab+ chemotherapy vs. placebo+ chemotherapy, followed by adjuvant pembrolizumab vs …
Background KEYNOTE-522 (NCT03036488) is a phase III study of neoadjuvant
pembrolizumab (pembro)+ chemotherapy (chemo) vs. placebo (pbo)+ chemo followed by
adjuvant pembro vs. pbo in patients (pts) with early-stage TNBC. In prior interim analyses,
pembro+ chemo showed a significant improvement in pCR and a favorable trend in EFS. We
present results from a prespecified interim analysis of KEYNOTE-522. Methods Pts with
previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0 …
pembrolizumab (pembro)+ chemotherapy (chemo) vs. placebo (pbo)+ chemo followed by
adjuvant pembro vs. pbo in patients (pts) with early-stage TNBC. In prior interim analyses,
pembro+ chemo showed a significant improvement in pCR and a favorable trend in EFS. We
present results from a prespecified interim analysis of KEYNOTE-522. Methods Pts with
previously untreated, non-metastatic, centrally confirmed TNBC (stage T1c N1-2 or T2-4 N0 …